For the quarter ending 2025-09-30, NXTC had $2,432K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,624 | -37,784 |
| Depreciation and amortization | 533 | 1,287 |
| Amortization of premiums and discounts on marketable securities | 46 | 386 |
| Stock-based compensation | 600 | 1,951 |
| Noncash operating lease expense | 148 | 288 |
| Prepaid expenses and other assets | -1,195 | 1,716 |
| Accounts payable | -153 | -2,809 |
| Accrued liabilities and other liabilities | -367 | -4,016 |
| Lease liabilities | -254 | -488 |
| Other long-term liabilities | -34 | -66 |
| Net cash used in operating activities | -6,268 | -35,707 |
| Sales and maturities of marketable securities | 8,700 | 37,558 |
| Purchases of marketable securities | 0 | 26,705 |
| Net cash provided by investing activities | 8,700 | 10,853 |
| Proceeds from issuance of common stock | 0 | 2,000 |
| Proceeds from shares issued under espp | 0 | 19 |
| Net cash provided by financing activities | 0 | 2,019 |
| Net increase (decrease) in cash and cash equivalents | 2,432 | -22,835 |
| Cash and cash equivalents at beginning of period | 27,727 | - |
| Cash and cash equivalents at end of period | 7,324 | - |
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)